The atlas targets 100 high-recognition entries across four non-equivalent classes:
regulator-approved peptide active substances;
clinical-stage investigational peptides;
endogenous or laboratory peptides with substantial scientific visibility;
products frequently marketed in the "research peptide" ecosystem.
Inclusion reflects scientific, clinical, regulatory, or public visibility—not an endorsement. Some marketed names refer to fragments, salts, metal complexes, mixtures, pegylated proteins, or poorly standardized products. The catalog classifies these boundary cases explicitly instead of assuming that every item sold as a peptide is a single well-defined peptide.
Evidence-search target
Each page is a structured narrative review of key evidence, not a claim to have captured every publication ever produced. Search dates, databases, query terms, and selection decisions must be recorded. Priority is given to:
current official product information and regulatory actions;
pivotal and confirmatory controlled human studies;
systematic reviews/meta-analyses that identify the evidence base;
representative early-phase human pharmacology;
decisive negative, terminated, retracted, or safety studies;
preclinical work only when human evidence is absent or the mechanism requires it, clearly labeled as non-human.
Refresh policy
Approval, trial, WADA, and legal-status claims are time-sensitive. Each carries
an as_of or last_verified date and should be rechecked before publication or
decision-making.